Ocugen found using ticker (OCGN) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 1 and 0.7 with the average target price sitting at 0.9. Now with the previous closing price of 0.29 this indicates there is a potential upside of 210.3%. The 50 day MA is 0.31 and the 200 day MA is 0.34. The market cap for the company is $130m. Find out more information at: http://www.ocugen.com
Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
